APA (7th ed.) Citation

Alleva, D. G., Gaur, A., Jin, L., Wegmann, D., Gottlieb, P. A., Pahuja, A., . . . Conlon, P. J. (2002). Immunological Characterization and Therapeutic Activity of an Altered-Peptide Ligand, NBI-6024, Based on the Immunodominant Type 1 Diabetes Autoantigen Insulin B-Chain (9–23) Peptide. Diabetes (New York, N.Y.), 51(7), 2126-2134. https://doi.org/10.2337/diabetes.51.7.2126

Chicago Style (17th ed.) Citation

Alleva, David G., et al. "Immunological Characterization and Therapeutic Activity of an Altered-Peptide Ligand, NBI-6024, Based on the Immunodominant Type 1 Diabetes Autoantigen Insulin B-Chain (9–23) Peptide." Diabetes (New York, N.Y.) 51, no. 7 (2002): 2126-2134. https://doi.org/10.2337/diabetes.51.7.2126.

MLA (9th ed.) Citation

Alleva, David G., et al. "Immunological Characterization and Therapeutic Activity of an Altered-Peptide Ligand, NBI-6024, Based on the Immunodominant Type 1 Diabetes Autoantigen Insulin B-Chain (9–23) Peptide." Diabetes (New York, N.Y.), vol. 51, no. 7, 2002, pp. 2126-2134, https://doi.org/10.2337/diabetes.51.7.2126.